REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of Two Nitrogens And Four Carbon Atoms (e.g., Pyridazines, Etc.) > 1,4-diazine As One Of The Cyclos > Piperazines (i.e., Fully Hydrogenated 1,4-diazines) > Plural Carbocyclic Rings Bonded Directly To The Same Acyclic Carbon Atom Which Is Attached Directly Or Indirectly To The Piperazine Ring By Nonionic Bonding Plural Carbocyclic Rings Bonded Directly To The Same Acyclic Carbon Atom Which Is Attached Directly Or Indirectly To The Piperazine Ring By Nonionic BondingPlural Carbocyclic Rings Bonded Directly To The Same Acyclic Carbon Atom Which Is Attached Directly Or Indirectly To The Piperazine Ring By Nonionic Bonding patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.11/16/06 - 20060258684 - 2-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl]ethoxy]acetic acid monohydrochloride as anti-allergenic compound and process for its production An anti-allergenic compound having therapeutic value and a process for its manufacture. The disclosure is directed to 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1piperazinyl]ethoxy]acetic acid monohydrochloride, to compositions containing 2-[2-[[(4chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid monohydrochloride, and to a process for the preparation of 2-[2-[[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid monohydrochloride. ... 11/02/06 - 20060247258 - Use of levocetirizine for the treatment of persistent allergic rhinitis The present invention relates to a pharmaceutical use of levocetirizine for the treatment of persistent allergic rhinitis. ... 10/12/06 - 20060229320 - Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine The invention provides a method for the treatment of allergic conditions by administering to a patient an effective amount of dextrorotatory dihydrochloride of 2-[2-[4-[(4-chloro-phenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid. The treatment is conducted in the absence of levorotatory dihydrochloride of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid. ... 06/22/06 - 20060135533 - Compound preparation for dizziness The use of cinnarizine and dimenhydrinate or their physiologically compatible salts in combination is described for the treatment of vertigo of any genesis. ... 06/08/06 - 20060122194 - Tablet comprising efletirizine and pseudoephedrine The present invention concerns a tablet comprising two distinct segments. More particularly the invention relates to combinations of two pharmaceutical substances and methods of treatment of allergic disorders. ... 02/09/06 - 20060030569 - Diarylmethyl piperazine derivatives, preparations thereof and uses thereof as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain, depression and anxiety. ... 01/26/06 - 20060019966 - Method for treating nervous system disorders and conditions The present invention is directed to selective dopamine reuptake inhibitors, including (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, (−)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS), chronic pain, and Shy Drager syndrome. ... 12/08/05 - 20050272746 - Inactive isomer compositions for use as drug-resistance-reversal agents and in prophylactic treatment A method of using inactive isomer compositions as drug-resistance-reversal agents and in prophylactic treatment includes the steps of selecting an antihistaminically-inactive isomer of a preselected antihistamine, and making stereoselective use of the antihistaminically-inactive isomer for a clinical purposes. The making step includes choosing one of the following clinical purposes for ... 11/03/05 - 20050245541 - Methods for treating alcoholism In the treatment of alcoholism, co-treatment with an active agent capable of offsetting unwanted adverse clinical manifestations to the treatment itself, for example, negative drug adverse clinical manifestations, greatly increases patient compliance. Increasing patient compliance, in turn, creates a better success rate and decreased recidivism or relapse. The current invention ... 10/13/05 - 20050227999 - Diarylamine derivatives as calcium channel blockers Compounds which are derivatives of diarylamine substituted piperazine and amino-piperidine are useful in treating conditions mediated by calcium ion channel activity. ... 10/13/05 - 20050227998 - Compositions and methods of decreasing nicotine withdrawal Administering to a patient an anticholinergic medication comprising scopolamine and hydroxyzine can alleviate the symptoms of nicotine withdrawal. Used in conjunction with pre- and post-administration counseling, smoking cessation rates may be significantly improved. ... 09/15/05 - 20050203105 - Composition and method for controlling alcohol-induced facial flushing in susceptible humans The invention is a treatment method for controlling alcohol-induced flushing of the face and torso in susceptible humans. The method is a treatment for the person prior to his imbibing alcohol; employs a nonsedating H1-receptor histamine antagonist and a H2-receptor histamine antagonist in combination as orally administered medicaments; and is ... 09/01/05 - 20050192290 - Treatment of behavioral disorders The present invention relates to a method for treating a behavior disorder comprising the administration of a therapeutically effective amount of antihistamine, such as ceterizine, fexofenadine; loratadine, and desloratadine. The behavioral disorders may include ADHD, anxieity, depression, and autism. The method may include the administration of the antihistamine in combination ... 08/18/05 - 20050182070 - Method for the treatment of allergic conditions The invention provides a method for the treatment of allergic conditions by administering to a patient an effective amount of dextrorotatory dihydrochloride of 2-[2-[4-[(4-chloro-phenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid. The treatment is conducted in the absence of levorotatory dihydrochloride of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid. ... 08/04/05 - 20050171120 - Stereoselective alkylation of chiral 2-methyl-4-protected piperazines In an illustrative embodiment, the present invention describes the synthesis of the following compound and similar compounds, in high stereochemical purity by a novel stereoselective alkylation process: ... 08/04/05 - 20050171119 - Pharmaceutical formulations with modified release The invention relates to a pharmaceutical composition which can be administered orally, containing efletirizine as active principle, and combining a fraction which allows immediate release and a fraction which allows prolonged release. ... 07/14/05 - 20050153983 - Synergistic combination of an opioid analgesic and a nsaid The invention relates to a combined pharmaceutical preparation comprising an opioid diarylmethyl piperazine compounds and a NSAID. Such a preparation in which the compounds are either given sequentially or simultaneously can be used for the treatment of pain diminishing the side-effects observed in conventional opioid treatments. ... 06/30/05 - 20050143394 - Phenylpiperazine cycloalkanol derivatives and methods of their use The present invention is directed to phenylpiperazine cycloalkanol derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and ... ### FreshPatents.com Support |